OA08801A - Antigènes de surface du virus de l'hépatite B et antigènes hybrides les contenant. - Google Patents

Antigènes de surface du virus de l'hépatite B et antigènes hybrides les contenant.

Info

Publication number
OA08801A
OA08801A OA59269A OA59269A OA08801A OA 08801 A OA08801 A OA 08801A OA 59269 A OA59269 A OA 59269A OA 59269 A OA59269 A OA 59269A OA 08801 A OA08801 A OA 08801A
Authority
OA
OAPI
Prior art keywords
antigens
hepatitis
hybrid
virus surface
surface antigens
Prior art date
Application number
OA59269A
Other languages
English (en)
French (fr)
Inventor
Cabezon Teresa
De Wilde Michel
Harfors Nigel
Original Assignee
Smith Kline Rit
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Smith Kline Rit filed Critical Smith Kline Rit
Publication of OA08801A publication Critical patent/OA08801A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
    • C07K14/445—Plasmodium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/78—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for Pseudomonas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16211—Human Immunodeficiency Virus, HIV concerning HIV gagpol
    • C12N2740/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
OA59269A 1987-01-30 1988-01-27 Antigènes de surface du virus de l'hépatite B et antigènes hybrides les contenant. OA08801A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US932587A 1987-01-30 1987-01-30

Publications (1)

Publication Number Publication Date
OA08801A true OA08801A (fr) 1989-03-31

Family

ID=21736956

Family Applications (1)

Application Number Title Priority Date Filing Date
OA59269A OA08801A (fr) 1987-01-30 1988-01-27 Antigènes de surface du virus de l'hépatite B et antigènes hybrides les contenant.

Country Status (20)

Country Link
EP (1) EP0278940A3 (de)
JP (1) JPS6463382A (de)
KR (1) KR880009130A (de)
CN (1) CN1031395A (de)
AP (1) AP56A (de)
AU (1) AU1093088A (de)
DD (3) DD284899A5 (de)
DK (1) DK43188A (de)
FI (1) FI880428L (de)
HU (1) HUT50876A (de)
IL (1) IL85216A0 (de)
MA (1) MA21169A1 (de)
NO (1) NO880395L (de)
NZ (1) NZ223297A (de)
OA (1) OA08801A (de)
PT (1) PT86640B (de)
SU (1) SU1746887A3 (de)
TN (1) TNSN88004A1 (de)
YU (1) YU17488A (de)
ZA (1) ZA88488B (de)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0300213A1 (de) * 1987-06-22 1989-01-25 Hexal-Pharma Gentechnik GmbH & Co. KG Virale, immunogen wirksame Peptidpartikel von Hepatitis A
NZ228774A (en) * 1988-04-25 1991-05-28 Phillips Petroleum Co Hbv particles containing pres 2 proteins and recombinant processes for their production in yeast cells
EP0345792A3 (de) * 1988-06-10 1991-05-02 F. Hoffmann-La Roche Ag HTLV-1/HIV-1-Fusionsproteine
FR2635532B1 (fr) * 1988-07-29 1992-05-22 Pasteur Institut Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant
CA2025481A1 (en) * 1989-09-19 1991-03-20 Peter J. Kniskern Vaccine for aids and hepatitis b
US5130248A (en) * 1989-09-19 1992-07-14 Merck & Co., Inc. Expression of fusion protein of HIV envelope and HBsAg
US5130247A (en) * 1989-09-19 1992-07-14 Merck & Co., Inc. Expression of fusion protein of HIV envelope and HBsAG
EP0491077A1 (de) * 1990-12-19 1992-06-24 Medeva Holdings B.V. Zusammensetzung verwendbar als therapeutisches Mittel gegen chronische virale Leberkrankheiten
AU2927892A (en) * 1991-11-16 1993-06-15 Smithkline Beecham Biologicals (Sa) Hybrid protein between cs from plasmodium and hbsag
EP0618924B1 (de) * 1991-12-23 2001-02-14 Bayer Corporation Hbv amplifizierungssonden zur verwendung in hybridisierungssandwichassay in der lösungsphase
US6297048B1 (en) 1992-02-04 2001-10-02 Chiron Corporation Hepatitis therapeutics
US5928902A (en) * 1992-02-27 1999-07-27 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBsAg
US6169171B1 (en) 1992-02-27 2001-01-02 Smithkline Beecham Biologicals (S.A.) Hybrid protein between CS from plasmodium and HBSAG
US6709828B1 (en) 1992-03-06 2004-03-23 N.V. Innogenetics S.A. Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing them and compositions containing them
US6667387B1 (en) 1996-09-30 2003-12-23 N.V. Innogenetics S.A. HCV core peptides
SG77551A1 (en) * 1992-03-06 2005-04-28 Innogenetics Nv Process for the determination of peptides corresponding to immunologically important epitopes and their use in a process for determination of antibodies or biotinylated peptides corresponding to immunologically important epitopes, a process for preparing
EP0565794A1 (de) * 1992-04-14 1993-10-20 British Biotech Pharmaceuticals Limited Induktion von CTL-Antworten
SG48365A1 (en) 1992-05-23 1998-04-17 Smithkline Beecham Biolog Combined vaccines comprising hepatitis b surface antigen and other antigens
CN1063343C (zh) * 1993-04-27 2001-03-21 中国科学院上海生物化学研究所 氨端带前表面抗原决定簇的乙型肝炎表面抗原蛋白
US6235888B1 (en) 1994-10-05 2001-05-22 The General Hospital Corporation Hepatitis C virus vaccine
RU2189254C2 (ru) * 1995-06-06 2002-09-20 Америкэн Хоум Продактс Корпорэйшн Вакцины против вирусов гепатита
AU2800797A (en) 1996-04-05 1997-10-29 Chiron Corporation Recombinant alphavirus-based vectors with reduced inhibition of cellular macromolecular synthesis
EP2298900A1 (de) 1996-09-17 2011-03-23 Novartis Vaccines and Diagnostics, Inc. Zusammensetzungen und Verfahren zur Behandlung intrazellulärer Erkrankungen
GB9623233D0 (en) 1996-11-07 1997-01-08 Smithkline Beecham Biolog Vaccine composition
KR100629028B1 (ko) 1998-10-16 2006-09-26 글락소스미스클라인 바이오로지칼즈 에스.에이. 애쥬번트 시스템 및 백신
UA79735C2 (uk) * 2000-08-10 2007-07-25 Глаксосмітклайн Байолоджікалз С.А. Очищення антигенів вірусу гепатиту b (hbv) для використання у вакцинах
CN100381171C (zh) * 2004-12-30 2008-04-16 成都生物制品研究所 含前s1、前s2和s抗原决定簇的乙肝表面抗原复合颗粒
CN102675430B (zh) * 2005-08-12 2014-08-27 上海贺普药业股份有限公司 乙型肝炎病毒表面l蛋白相关肽
EP2441469A1 (de) 2006-03-14 2012-04-18 Oregon Health and Science University Verfahren zur Erzeugung einer Immunantwort auf Tuberculosis
JP5814507B2 (ja) 2006-09-07 2015-11-17 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
KR100836745B1 (ko) * 2007-01-31 2008-06-10 (주)두비엘 Ｈｂｖ 백신 및 그의 제조 방법
WO2008106551A2 (en) 2007-02-28 2008-09-04 The Govt. Of The U.S.A. As Represented By The Secretary Of The Dept. Of Health & Human Serv. Brachyury polypeptides and methods for use
JP2010525035A (ja) 2007-05-02 2010-07-22 グラクソスミスクライン バイオロジカルズ ソシエテ アノニム ワクチン
WO2009143524A2 (en) 2008-05-23 2009-11-26 The Regents Of The University Of Michigan Nanoemulsion vaccines
WO2010099472A2 (en) 2009-02-27 2010-09-02 The U.S.A. Of America, As Represented By The Secretary, Department Of Health And Human Services Spanx-b polypeptides and their use
GB201105981D0 (en) 2011-04-08 2011-05-18 Glaxosmithkline Biolog Sa Novel process
WO2014043518A1 (en) 2012-09-14 2014-03-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Brachyury protein, non-poxvirus non-yeast vectors encoding brachyury protein, and their use
EP4137150A1 (de) 2015-08-03 2023-02-22 The United States of America, as represented by the Secretary, Department of Health and Human Services Brachyury-deletionsmutanten, nichthefevektoren zur codierung von brachyury-deletionsmutanten und verwendung davon
CN119780431A (zh) * 2025-03-11 2025-04-08 泰州蕾灵百奥生物科技有限公司 一种用于检测猪流行性腹泻的试剂盒及其制备方法

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2145092B (en) * 1983-01-28 1988-04-07 Univ New York Protective peptide antigen
IL69202A (en) * 1982-09-08 1991-08-16 Smith Kline Rit Surface antigen polypeptides of hbv virus produced in yeast and the preparation thereof
ATE73349T1 (de) * 1984-06-18 1992-03-15 Chiron Corp Hepatitisoberflaechenantigenpartikelvakzin.
EP0171908A3 (de) * 1984-07-11 1987-07-15 Takeda Chemical Industries, Ltd. Hepatitis-B-Virus-Oberflächenantigen und dessen Herstellung
GB8421282D0 (en) * 1984-08-22 1984-09-26 Connaught Lab Multispecific antigenic proteins
ATE70308T1 (de) * 1984-09-12 1991-12-15 Chiron Corp Hybridpartikel-immunogene.
EP0180012A1 (de) * 1984-10-27 1986-05-07 Wolfram H. Prof. Dr. Gerlich Immunogene Polypeptidsequenz des Hepatitis B-Virus
CN86100979A (zh) * 1985-02-07 1986-12-17 史密丝克莱恩贝克曼公司 疟疾疫苗的制备方法
US4774175A (en) * 1985-03-01 1988-09-27 Centocor, Inc. Immunochemical methods for the detection of antibody against HTLV-III
US4683294A (en) * 1985-04-03 1987-07-28 Smith Kline Rit, S.A. Process for the extraction and purification of proteins from culture media producing them
DE3689899T2 (de) * 1985-04-08 1994-09-15 Amgen Verfahren und hybridpromotor zur steuerung der exogenen gentranskription.
FR2581394B1 (fr) * 1985-05-02 1988-08-05 Grp Genie Genetique Particules ayant les proprietes immunogenes de l'antigene hbs et portant un site antigenique etranger aux epitopes portes par l'antigene hbs, vecteurs et cellules animales pour la production de telles particules et compositions contenant de telles particules pour la production de vaccins mixtes
US4816564A (en) * 1986-01-31 1989-03-28 Merck & Co., Inc. Method for producing hepatitis B virus proteins in yeast
CA1310602C (en) * 1986-06-03 1992-11-24 Hajime Horii Yeast promoter and process for preparing heterologous protein

Also Published As

Publication number Publication date
KR880009130A (ko) 1988-09-14
EP0278940A2 (de) 1988-08-17
NO880395L (no) 1988-08-01
CN1031395A (zh) 1989-03-01
HUT50876A (en) 1990-03-28
AU1093088A (en) 1988-08-04
DD285612A5 (de) 1990-12-19
FI880428A7 (fi) 1988-07-31
JPS6463382A (en) 1989-03-09
DD284899A5 (de) 1990-11-28
DK43188A (da) 1988-07-31
MA21169A1 (fr) 1988-10-01
PT86640A (pt) 1988-02-01
YU17488A (en) 1991-02-28
TNSN88004A1 (fr) 1990-07-10
PT86640B (pt) 1992-01-31
SU1746887A3 (ru) 1992-07-07
FI880428A0 (fi) 1988-01-29
DK43188D0 (da) 1988-01-28
NO880395D0 (no) 1988-01-29
FI880428L (fi) 1988-09-13
AP56A (en) 1989-09-26
EP0278940A3 (de) 1988-12-07
DD285994A5 (de) 1991-01-10
AP8800078A0 (en) 1987-11-01
ZA88488B (en) 1988-10-26
NZ223297A (en) 1991-06-25
IL85216A0 (en) 1988-07-31

Similar Documents

Publication Publication Date Title
OA08801A (fr) Antigènes de surface du virus de l'hépatite B et antigènes hybrides les contenant.
LU90911I2 (fr) Antig-ne recombinant comprenant les s-quences pre-S1 et S du virus de l'h-patite B ingr-dient actif de hepacare
FI945483L (fi) Hepatiitti B - pinta-antigeenejä ja muita antigeenejä sisältäviä yhdistelmärokotteita
PT85137A (en) T and b cell epitopes of the pre-s region of hepatitis b virus surface antigen
FR2556720B1 (fr) Derives de l'amidine et tonicardiaques les contenant
FR2620163B1 (fr) Blindage notamment pour coffre-fort et coffre-fort s'y rapportant
KR890701743A (ko) B형 간염 표면 항원 백신
FR2606281B1 (fr) Antigene du virus de l'hepatite b et procede pour sa production
FR2597197B1 (fr) Recipient de combustion du type cheminee
FR2550203B1 (fr) Peptides synthetiques immunogenes porteurs d'un epitope caracteristique de l'antigene de surface du virus de l'hepatite b et compositions les contenant
IT7830790A0 (it) Reagenti per la rivelazione dell'antigene-e e anticorpo-e di epatite b.
OA06865A (fr) Nappe d'enveloppes successives et enveloppes de cette nappe.
IT1225454B (it) Cinematismo composto moltiplicatore di corse e velocita'.
DE3175439D1 (en) Non-a, non-b hepatitis assay and vaccine
FR2486802B1 (fr) Purification de l'antigene de surface de l'hepatite b (hbsag)
ES1001693Y (es) Braguita infantil mejorada
GB8622883D0 (en) Expression of hepatitis b viral antigens
GB8621578D0 (en) Hepatitis b viral antigens
ES1002646Y (es) Banera infantil mejorada
IE880242L (en) Hepatitis b virus antigens.
IT1107209B (it) Antigene di superficie dell'epatite b
ES264016Y (es) "tienda de campana de juguete".
IE851705L (en) Hepatitis B Virus Surfact Antigen and Production Thereof
ES262689Y (es) "aspirador aero-termico".
ES248503Y (es) Cubo infantil perfeccionado